Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Muraglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 19/20 | 1.00 |
| ▸ | PPARG known ✓ | P37231 | 17/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13722049 | 0.96 | PPARA (0.93) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13718146 | 0.96 | PPARA (0.93) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL6073227 | 0.95 | PPARA (0.90) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL8215885 | 0.94 | PPARA (0.88) | PPARAPPARG | |
| SCHEMBL6073514 | 0.94 | PPARA (0.88) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13721992 | 0.93 | PPARA (0.87) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13717685 | 0.93 | PPARA (0.87) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13717584 | 0.93 | PPARA (0.89) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13718351 | 0.93 | PPARA (0.89) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13717851 | 0.93 | PPARA (0.87) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137661-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2026-05-21 | — | — | US | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4615433-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2025-09-17 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-13 | — | — | US | claimed |
| WO-2016127019-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. (US) | 2016-08-11 | — | — | WO | claimed |
| US-20160128994-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-05-12 | — | — | US | claimed |
| EP-3003303-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | Indiana University Research And Technology Corporation (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014197820-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-12-11 | — | — | WO | claimed |
| EP-2253325-A1 | AGENT FOR ENHANCING CORNEAL EPITHELIAL BARRIER FUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2010-11-24 | — | — | EP | claimed |
| US-7348329-B2 | Therapeutic agent for keratoconjunctival disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-25 | — | — | US | claimed |
| US-20070093514-A1 | Therapeutic agent for keratoconjunctival disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-04-26 | — | — | US | claimed |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| EP-1681054-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVA DISORDER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-07-19 | — | — | EP | claimed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137661-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885CYP2C9 2389/4885 |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | PDE4D, PDE4A, PDE4B | PPARA 210/4885PPARG 129/4885CYP2C9 3760/4885 |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PPARD, NR1H4, PPARG | PPARA 4/4885PPARG 3/4885CYP2C9 402/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARA 1336/4885PPARG 467/4885CYP2C9 1471/4885 |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | PPARG, PPARA, NR3C1 | PPARA 2/4885PPARG 1/4885CYP2C9 2362/4885 |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PPARD, NR1H4, PPARG | PPARA 4/4885PPARG 3/4885CYP2C9 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.